BSE Live
Oct 03, 16:01Prev. Close
1958.65
Open Price
1946.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 03, 15:56Prev. Close
1959.20
Open Price
1959.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1980.20 (88)
Balance Sheet of Glenmark Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
EQUITIES AND LIABILITIES | ||||||
SHAREHOLDER'S FUNDS | ||||||
Equity Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | |
Total Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | |
Reserves and Surplus | 24,475.74 | 22,939.89 | 17,849.25 | 16,710.37 | 14,781.29 | |
Total Reserves and Surplus | 24,475.74 | 22,939.89 | 17,849.25 | 16,710.37 | 14,781.29 | |
Total Shareholders Funds | 24,503.96 | 22,970.62 | 17,877.46 | 16,738.59 | 14,809.51 | |
NON-CURRENT LIABILITIES | ||||||
Long Term Borrowings | 0.00 | 0.00 | 2,660.82 | 2,571.74 | 3,112.58 | |
Deferred Tax Liabilities [Net] | 58.26 | 0.00 | 0.00 | 0.00 | 0.00 | |
Other Long Term Liabilities | 225.16 | 154.39 | 405.87 | 163.09 | 192.09 | |
Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Non-Current Liabilities | 283.42 | 154.39 | 3,066.69 | 2,734.84 | 3,304.67 | |
CURRENT LIABILITIES | ||||||
Short Term Borrowings | 698.82 | 657.24 | 495.58 | 1,098.61 | 513.02 | |
Trade Payables | 2,122.66 | 2,700.38 | 2,093.13 | 1,938.80 | 1,622.67 | |
Other Current Liabilities | 298.64 | 816.74 | 956.05 | 304.60 | 258.38 | |
Short Term Provisions | 125.79 | 115.03 | 97.01 | 99.05 | 109.28 | |
Total Current Liabilities | 3,245.91 | 4,289.39 | 3,641.77 | 3,441.06 | 2,503.35 | |
Total Capital And Liabilities | 28,033.28 | 27,414.39 | 24,585.92 | 22,914.48 | 20,617.52 | |
ASSETS | ||||||
NON-CURRENT ASSETS | ||||||
Tangible Assets | 1,785.23 | 1,538.58 | 1,488.67 | 1,468.53 | 1,490.28 | |
Intangible Assets | 193.95 | 217.67 | 257.28 | 283.79 | 232.22 | |
Capital Work-In-Progress | 121.34 | 175.50 | 159.07 | 101.17 | 93.31 | |
Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Fixed Assets | 2,133.74 | 1,953.91 | 1,918.28 | 1,861.37 | 1,853.89 | |
Non-Current Investments | 15,194.91 | 12,964.79 | 10,334.01 | 8,559.39 | 6,989.95 | |
Deferred Tax Assets [Net] | 0.00 | 165.85 | 946.75 | 923.27 | 853.29 | |
Long Term Loans And Advances | 5,754.25 | 7,505.66 | 6,874.07 | 7,078.63 | 5,930.70 | |
Other Non-Current Assets | 172.71 | 142.71 | 127.63 | 88.91 | 80.57 | |
Total Non-Current Assets | 23,255.61 | 22,732.92 | 20,200.75 | 18,511.56 | 15,708.40 | |
CURRENT ASSETS | ||||||
Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Inventories | 1,369.31 | 1,142.69 | 1,090.21 | 951.66 | 762.39 | |
Trade Receivables | 2,550.16 | 2,484.47 | 2,505.66 | 2,678.32 | 2,488.75 | |
Cash And Cash Equivalents | 132.74 | 129.15 | 93.79 | 29.63 | 15.79 | |
Short Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
OtherCurrentAssets | 725.47 | 925.16 | 695.51 | 743.31 | 1,642.20 | |
Total Current Assets | 4,777.67 | 4,681.47 | 4,385.18 | 4,402.93 | 4,909.12 | |
Total Assets | 28,033.28 | 27,414.39 | 24,585.92 | 22,914.48 | 20,617.52 | |
OTHER ADDITIONAL INFORMATION | ||||||
CONTINGENT LIABILITIES, COMMITMENTS | ||||||
Contingent Liabilities | 4,308.34 | 2,658.49 | 3,922.95 | 3,699.68 | 4,012.99 | |
CIF VALUE OF IMPORTS | ||||||
Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
EXPENDITURE IN FOREIGN EXCHANGE | ||||||
Expenditure In Foreign Currency | 2,321.69 | 1,963.59 | 1,271.22 | 1,348.24 | 1,202.32 | |
REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
EARNINGS IN FOREIGN EXCHANGE | ||||||
FOB Value Of Goods | -- | -- | -- | -- | -- | |
Other Earnings | 4,631.03 | 3,220.74 | 4,646.37 | 3,214.23 | 3,575.27 | |
BONUS DETAILS | ||||||
Bonus Equity Share Capital | 15.84 | 15.84 | 15.84 | 15.84 | 15.84 | |
NON-CURRENT INVESTMENTS | ||||||
Non-Current Investments Quoted Market Value | 0.11 | 745.16 | 3,975.01 | 4,659.12 | 0.07 | |
Non-Current Investments Unquoted Book Value | 15,194.80 | 12,219.63 | 10,332.50 | 8,557.90 | 6,989.88 | |
CURRENT INVESTMENTS | ||||||
Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
03.12.2024
Glenmark Consolidated September 2024 Net Sales at Rs 3,433.80 crore, up 7.06% Y-o-Y
20.11.2024
Glenmark Standalone September 2024 Net Sales at Rs 2,636.10 crore, up 18.03% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015